{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,9]],"date-time":"2026-11-09T17:25:18Z","timestamp":1794245118693,"version":"4.9.0"},"reference-count":77,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2024,7,8]],"date-time":"2024-07-08T00:00:00Z","timestamp":1720396800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,7,8]],"date-time":"2024-07-08T00:00:00Z","timestamp":1720396800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Gastrointest Canc"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1007\/s12029-024-01078-8","type":"journal-article","created":{"date-parts":[[2024,7,8]],"date-time":"2024-07-08T13:02:27Z","timestamp":1720443747000},"page":"1026-1057","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["The Current Landscape of Clinical Trials for Immunotherapy in Pancreatic Cancer: A State-of-the-Art Review"],"prefix":"10.1007","volume":"55","author":[{"given":"Zouina","family":"Sarfraz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Azza","family":"Sarfraz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad Danyal","family":"Farooq","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Musfira","family":"Khalid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khadija","family":"Cheema","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Faheem","family":"Javad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taleah","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zainab","family":"Pervaiz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muzna","family":"Sarfraz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Jaan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Subhan","family":"Sadiq","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junaid","family":"Anwar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,7,8]]},"reference":[{"key":"1078_CR1","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1016\/j.cgh.2020.02.054","volume":"19","author":"N Khalaf","year":"2021","unstructured":"Khalaf N, El-Serag HB, Abrams HR, et al. Burden of pancreatic cancer: from epidemiology to practice. Clin Gastroenterol Hepatol. 2021;19:876\u201384.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"1078_CR2","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/j.canlet.2018.03.040","volume":"425","author":"J Xu","year":"2018","unstructured":"Xu J, Wang L, Cheng Y, et al. Immunotherapy for pancreatic cancer: a long and hopeful journey. Cancer Lett. 2018;425:143\u201351.","journal-title":"Cancer Lett"},{"key":"1078_CR3","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1177\/1756283X16667909","volume":"10","author":"K Thind","year":"2017","unstructured":"Thind K, Padrnos LJ, Ramanathan RK, et al. Immunotherapy in pancreatic cancer treatment: a new frontier. Ther Adv Gastroenterol. 2017;10:168\u201394.","journal-title":"Ther Adv Gastroenterol"},{"key":"1078_CR4","doi-asserted-by":"publisher","first-page":"11","DOI":"10.3322\/caac.21166","volume":"63","author":"R Siegel","year":"2013","unstructured":"Siegel R, Naishadham D, Jemal A. Global cancer statistics. CA Cancer J Clin. 2013;63:11\u201330.","journal-title":"CA Cancer J Clin"},{"key":"1078_CR5","doi-asserted-by":"publisher","first-page":"6287","DOI":"10.1158\/1078-0432.CCR-18-0900","volume":"27","author":"R Hester","year":"2021","unstructured":"Hester R, Mazur PK, McAllister F. Immunotherapy in pancreatic adenocarcinoma: beyond \u201ccopy\/paste.\u201d Clin Cancer Res. 2021;27:6287\u201397.","journal-title":"Clin Cancer Res"},{"key":"1078_CR6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s40425-016-0119-z","volume":"4","author":"PR Kunk","year":"2016","unstructured":"Kunk PR, Bauer TW, Slingluff CL, et al. From bench to bedside a comprehensive review of pancreatic cancer immunotherapy. J Immunother Cancer. 2016;4:1\u201312.","journal-title":"J Immunother Cancer"},{"key":"1078_CR7","doi-asserted-by":"publisher","first-page":"e476","DOI":"10.1016\/S1470-2045(13)70172-4","volume":"14","author":"W Hartwig","year":"2013","unstructured":"Hartwig W, Werner J, J\u00e4ger D, et al. Improvement of surgical results for pancreatic cancer. Lancet Oncol. 2013;14:e476\u201385.","journal-title":"Lancet Oncol"},{"key":"1078_CR8","first-page":"5","volume-title":"Seminars in Oncology","author":"MJ Moore","year":"2005","unstructured":"Moore MJ. Brief communication: a new combination in the treatment of advanced pancreatic cancer. In: Seminars in Oncology. Elsevier; 2005. p. 5\u20136."},{"key":"1078_CR9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12916-018-1215-3","volume":"16","author":"H Zhu","year":"2018","unstructured":"Zhu H, Li T, Du Y, et al. Pancreatic cancer: challenges and opportunities. BMC Med. 2018;16:1\u20133.","journal-title":"BMC Med"},{"key":"1078_CR10","doi-asserted-by":"publisher","first-page":"2231","DOI":"10.1200\/JCO.2008.20.0238","volume":"27","author":"E Van Cutsem","year":"2009","unstructured":"Van Cutsem E, Vervenne WL, Bennouna J, et al. Phase III trial of bevacizumab in combination with gemcitabine and erlotinib in patients with metastatic pancreatic cancer. J Clin Oncol. 2009;27:2231\u20137.","journal-title":"J Clin Oncol"},{"key":"1078_CR11","doi-asserted-by":"publisher","first-page":"30","DOI":"10.20517\/2394-4722.2018.13","volume":"4","author":"NP Pereira","year":"2018","unstructured":"Pereira NP, Corr\u00eaa JR. Pancreatic cancer: treatment approaches and trends. J Cancer Metastasis Treat. 2018;4:30.","journal-title":"J Cancer Metastasis Treat"},{"key":"1078_CR12","doi-asserted-by":"crossref","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, Shamseer L, Tetzlaff JM, Akl EA, Brennan SE, Chou R. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372.","DOI":"10.1136\/bmj.n71"},{"issue":"16","key":"1078_CR13","doi-asserted-by":"publisher","first-page":"4574","DOI":"10.1158\/1078-0432.CCR-21-1047","volume":"27","author":"KT Byrne","year":"2021","unstructured":"Byrne KT, Betts CB, Mick R, Sivagnanam S, Bajor DL, Laheru DA, Chiorean EG, O\u2019Hara MH, Liudahl SM, Newcomb C, Alanio C. Neoadjuvant selicrelumab, an agonist CD40 antibody, induces changes in the tumor microenvironment in patients with resectable pancreatic cancer. Clin Cancer Res. 2021;27(16):4574\u201386.","journal-title":"Clin Cancer Res."},{"key":"1078_CR14","doi-asserted-by":"publisher","first-page":"e808","DOI":"10.1634\/theoncologist.2019-0473","volume":"25","author":"SD Kamath","year":"2020","unstructured":"Kamath SD, Kalyan A, Kircher S, et al. Ipilimumab and gemcitabine for advanced pancreatic cancer: a phase Ib study. Oncologist. 2020;25:e808\u201315.","journal-title":"Oncologist"},{"key":"1078_CR15","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1053\/j.gastro.2018.03.029","volume":"155","author":"GL Beatty","year":"2018","unstructured":"Beatty GL, O\u2019Hara MH, Lacey SF, et al. Activity of mesothelin-specific chimeric antigen receptor T cells against pancreatic carcinoma metastases in a phase 1 trial. Gastroenterology. 2018;155:29\u201332.","journal-title":"Gastroenterology"},{"key":"1078_CR16","doi-asserted-by":"crossref","unstructured":"Melisi D, Oh D-Y, Hollebecque A, et al. Safety and activity of the TGF\u03b2 receptor I kinase inhibitor galunisertib plus the anti-PD-L1 antibody durvalumab in metastatic pancreatic cancer. J Immunother Cancer; 9.","DOI":"10.1136\/jitc-2020-002068"},{"key":"1078_CR17","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1007\/s00280-016-3108-5","volume":"78","author":"MS Beg","year":"2016","unstructured":"Beg MS, Azad NS, Patel SP, et al. A phase 1 dose-escalation study of NEO-102 in patients with refractory colon and pancreatic cancer. Cancer Chemother Pharmacol. 2016;78:577\u201384.","journal-title":"Cancer Chemother Pharmacol"},{"key":"1078_CR18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13045-017-0459-2","volume":"10","author":"S Mehrotra","year":"2017","unstructured":"Mehrotra S, Britten CD, Chin S, et al. Vaccination with poly (IC: LC) and peptide-pulsed autologous dendritic cells in patients with pancreatic cancer. J Hematol Oncol. 2017;10:1\u201313.","journal-title":"J Hematol Oncol"},{"key":"1078_CR19","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1016\/j.surg.2020.04.057","volume":"168","author":"C O\u2019Neill","year":"2020","unstructured":"O\u2019Neill C, Hayat T, Hamm J, Healey M, Zheng Q, Li Y, II Martin RC, et al. A phase 1b trial of concurrent immunotherapy and irreversible electroporation in the treatment of locally advanced pancreatic adenocarcinoma. Surgery. 2020;168:610\u20136.","journal-title":"Surgery"},{"key":"1078_CR20","first-page":"105","volume":"37","author":"S Nishida","year":"2014","unstructured":"Nishida S, Koido S, Takeda Y, et al. Wilms tumor gene (WT1) peptide\u2013based cancer vaccine combined with gemcitabine for patients with advanced pancreatic cancer. J Immunother (Hagerstown, Md: 1997). 2014;37:105.","journal-title":"J Immunother (Hagerstown, Md: 1997)"},{"key":"1078_CR21","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1007\/s00262-015-1679-3","volume":"64","author":"LK Aguilar","year":"2015","unstructured":"Aguilar LK, Shirley LA, Chung VM, et al. Gene-mediated cytotoxic immunotherapy as adjuvant to surgery or chemoradiation for pancreatic adenocarcinoma. Cancer Immunol Immunother. 2015;64:727\u201336.","journal-title":"Cancer Immunol Immunother"},{"key":"1078_CR22","first-page":"2217","volume":"38","author":"R Yanagisawa","year":"2018","unstructured":"Yanagisawa R, Koizumi T, Koya T, et al. WT1-pulsed dendritic cell vaccine combined with chemotherapy for resected pancreatic cancer in a phase I study. Anticancer Res. 2018;38:2217\u201325.","journal-title":"Anticancer Res"},{"key":"1078_CR23","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.ejca.2022.03.015","volume":"169","author":"SP Lau","year":"2022","unstructured":"Lau SP, Klaase L, Vink M, et al. Autologous dendritic cells pulsed with allogeneic tumour cell lysate induce tumour-reactive T-cell responses in patients with pancreatic cancer: a phase I study. Eur J Cancer. 2022;169:20\u201331.","journal-title":"Eur J Cancer"},{"key":"1078_CR24","first-page":"36","volume":"37","author":"N Suzuki","year":"2014","unstructured":"Suzuki N, Hazama S, Ueno T, et al. A phase I clinical trial of vaccination with KIF20A-derived peptide in combination with gemcitabine for patients with advanced pancreatic cancer. J Immunother (Hagerstown, Md: 1997). 2014;37:36.","journal-title":"J Immunother (Hagerstown, Md: 1997)"},{"key":"1078_CR25","doi-asserted-by":"publisher","first-page":"1832","DOI":"10.3389\/fimmu.2019.01832","volume":"10","author":"M Bassani-Sternberg","year":"2019","unstructured":"Bassani-Sternberg M, Digklia A, Huber F, et al. A phase Ib study of the combination of personalized autologous dendritic cell vaccine, aspirin, and standard of care adjuvant chemotherapy followed by nivolumab for resected pancreatic adenocarcinoma\u2014a proof of antigen discovery feasibility in three patients. Front Immunol. 2019;10:1832.","journal-title":"Front Immunol"},{"key":"1078_CR26","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1111\/cas.12046","volume":"104","author":"H Kameshima","year":"2013","unstructured":"Kameshima H, Tsuruma T, Kutomi G, et al. Immunotherapeutic benefit of \u03b1-interferon (IFN\u03b1) in survivin2 B-derived peptide vaccination for advanced pancreatic cancer patients. Cancer Sci. 2013;104:124\u20139.","journal-title":"Cancer Sci"},{"key":"1078_CR27","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1111\/cas.12621","volume":"106","author":"S Mayanagi","year":"2015","unstructured":"Mayanagi S, Kitago M, Sakurai T, et al. Phase I pilot study of Wilms tumor gene 1 peptide-pulsed dendritic cell vaccination combined with gemcitabine in pancreatic cancer. Cancer Sci. 2015;106:397\u2013406.","journal-title":"Cancer Sci"},{"key":"1078_CR28","doi-asserted-by":"publisher","first-page":"1750","DOI":"10.1093\/annonc\/mdu205","volume":"25","author":"M Aglietta","year":"2014","unstructured":"Aglietta M, Barone C, Sawyer MB, et al. A phase I dose escalation trial of tremelimumab (CP-675,206) in combination with gemcitabine in chemotherapy-naive patients with metastatic pancreatic cancer. Ann Oncol. 2014;25:1750\u20135.","journal-title":"Ann Oncol"},{"key":"1078_CR29","doi-asserted-by":"publisher","first-page":"6286","DOI":"10.1158\/1078-0432.CCR-13-1320","volume":"19","author":"GL Beatty","year":"2013","unstructured":"Beatty GL, Torigian DA, Chiorean EG, et al. A phase I study of an agonist CD40 monoclonal antibody (CP-870,893) in combination with gemcitabine in patients with advanced pancreatic ductal adenocarcinoma. Clin Cancer Res. 2013;19:6286\u201395.","journal-title":"Clin Cancer Res"},{"key":"1078_CR30","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1097\/COC.0000000000000599","volume":"42","author":"C Lin","year":"2019","unstructured":"Lin C, Verma V, Lazenby A, et al. Phase I\/II trial of neoadjuvant oregovomab-based chemoimmunotherapy followed by stereotactic body radiotherapy and nelfinavir for locally advanced pancreatic adenocarcinoma. Am J Clin Oncol. 2019;42:755.","journal-title":"Am J Clin Oncol"},{"issue":"6","key":"1078_CR31","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1158\/2767-9764.CRC-23-0137","volume":"3","author":"J Wang","year":"2023","unstructured":"Wang J, Cheng X, Jin Y, et al. Safety and clinical response to combined immunotherapy with autologous iNKT cells and PD-1+CD8+ T cells in patients failing first-line chemotherapy in stage IV pancreatic cancer. Cancer Res Commun. 2023;3(6):991\u20131003. https:\/\/doi.org\/10.1158\/2767-9764.CRC-23-0137. Published 2023 Jun 7.","journal-title":"Cancer Res Commun"},{"issue":"7963","key":"1078_CR32","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1038\/s41586-023-06063-y","volume":"618","author":"LA Rojas","year":"2023","unstructured":"Rojas LA, Sethna Z, Soares KC, et al. Personalized RNA neoantigen vaccines stimulate T cells in pancreatic cancer. Nature. 2023;618(7963):144\u201350. https:\/\/doi.org\/10.1038\/s41586-023-06063-y.","journal-title":"Nature."},{"key":"1078_CR33","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1479-5876-11-291","volume":"11","author":"S Asahara","year":"2013","unstructured":"Asahara S, Takeda K, Yamao K, et al. Phase I\/II clinical trial using HLA-A24-restricted peptide vaccine derived from KIF20A for patients with advanced pancreatic cancer. J Transl Med. 2013;11:1\u201313.","journal-title":"J Transl Med"},{"key":"1078_CR34","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1038\/s41392-020-00260-1","volume":"5","author":"M Lin","year":"2020","unstructured":"Lin M, Zhang X, Liang S, et al. Irreversible electroporation plus allogenic V\u03b39V\u03b42 T cells enhances antitumor effect for locally advanced pancreatic cancer patients. Signal Transduct Target Ther. 2020;5:215.","journal-title":"Signal Transduct Target Ther"},{"key":"1078_CR35","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.1038\/s41591-022-01829-9","volume":"28","author":"LJ Padr\u00f3n","year":"2022","unstructured":"Padr\u00f3n LJ, Maurer DM, O\u2019Hara MH, et al. Sotigalimab and\/or nivolumab with chemotherapy in first-line metastatic pancreatic cancer: clinical and immunologic analyses from the randomized phase 2 PRINCE trial. Nat Med. 2022;28:1167\u201377.","journal-title":"Nat Med"},{"key":"1078_CR36","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1007\/s11605-012-2064-6","volume":"17","author":"JM Hardacre","year":"2013","unstructured":"Hardacre JM, Mulcahy M, Small W, et al. Addition of algenpantucel-L immunotherapy to standard adjuvant therapy for pancreatic cancer: a phase 2 study. J Gastrointest Surg. 2013;17:94\u2013101.","journal-title":"J Gastrointest Surg"},{"key":"1078_CR37","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1158\/2326-6066.CIR-19-0650","volume":"8","author":"N Nair","year":"2020","unstructured":"Nair N, Chen S-Y, Lemmens E, et al. Single-cell immune competency signatures associate with survival in Phase II GVAX and CRS-207 randomized studies in patients with metastatic pancreatic cancer Cellular biomarkers in pancreatic cancer. Cancer Immunol Res. 2020;8:609\u201317.","journal-title":"Cancer Immunol Res"},{"key":"1078_CR38","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1007\/s00262-014-1566-3","volume":"63","author":"MJ Chung","year":"2014","unstructured":"Chung MJ, Park JY, Bang S, et al. Phase II clinical trial of ex vivo-expanded cytokine-induced killer cells therapy in advanced pancreatic cancer. Cancer Immunol Immunother. 2014;63:939\u201346.","journal-title":"Cancer Immunol Immunother"},{"key":"1078_CR39","doi-asserted-by":"crossref","unstructured":"Overman M, Javle M, Davis RE, et al. Randomized phase II study of the Bruton tyrosine kinase inhibitor acalabrutinib, alone or with pembrolizumab in patients with advanced pancreatic cancer. J Immunother Cancer; 8.","DOI":"10.1136\/jitc-2020-000587"},{"key":"1078_CR40","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1111\/cas.13113","volume":"108","author":"N Suzuki","year":"2017","unstructured":"Suzuki N, Hazama S, Iguchi H, et al. Phase II clinical trial of peptide cocktail therapy for patients with advanced pancreatic cancer: VENUS-PC study. Cancer Sci. 2017;108:73\u201380.","journal-title":"Cancer Sci"},{"key":"1078_CR41","doi-asserted-by":"publisher","first-page":"2378","DOI":"10.1111\/cas.14106","volume":"110","author":"H Shima","year":"2019","unstructured":"Shima H, Tsurita G, Wada S, et al. Randomized phase II trial of survivin 2B peptide vaccination for patients with HLA-A24-positive pancreatic adenocarcinoma. Cancer Sci. 2019;110:2378\u201385.","journal-title":"Cancer Sci"},{"key":"1078_CR42","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1111\/cas.12674","volume":"106","author":"H Yamaue","year":"2015","unstructured":"Yamaue H, Tsunoda T, Tani M, Miyazawa M, Yamao K, Mizuno N, Okusaka T, Ueno H, Boku N, Fukutomi A, Ishii H. Randomized phase II\/III clinical trial of elpamotide for patients with advanced pancreatic cancer: PEGASUS-PC Study. Cancer Sci. 2015;106:883\u201390.","journal-title":"Cancer Sci."},{"key":"1078_CR43","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1097\/SLA.0000000000004669","volume":"275","author":"DB Hewitt","year":"2022","unstructured":"Hewitt DB, Nissen N, Hatoum H, et al. A phase 3 randomized clinical trial of chemotherapy with or without algenpantucel-L (hyperacute-pancreas) immunotherapy in subjects with borderline resectable or locally advanced unresectable pancreatic cancer. Ann Surg. 2022;275:45\u201353.","journal-title":"Ann Surg"},{"key":"1078_CR44","doi-asserted-by":"publisher","first-page":"5020","DOI":"10.1038\/s41467-022-32591-8","volume":"13","author":"DJ Renouf","year":"2022","unstructured":"Renouf DJ, Loree JM, Knox JJ, et al. The CCTG PA.7 phase II trial of gemcitabine and nab-paclitaxel with or without durvalumab and tremelimumab as initial therapy in metastatic pancreatic ductal adenocarcinoma. Nat Commun. 2022;13:5020. https:\/\/doi.org\/10.1038\/s41467-022-32591-8.","journal-title":"Nat Commun"},{"key":"1078_CR45","doi-asserted-by":"publisher","first-page":"3650","DOI":"10.1038\/s41467-023-39196-9","volume":"14","author":"T Heumann","year":"2023","unstructured":"Heumann T, Judkins C, Li K, et al. A platform trial of neoadjuvant and adjuvant antitumor vaccination alone or in combination with PD-1 antagonist and CD137 agonist antibodies in patients with resectable pancreatic adenocarcinoma. Nat Commun. 2023;14:3650. https:\/\/doi.org\/10.1038\/s41467-023-39196-9.","journal-title":"Nat Commun"},{"key":"1078_CR46","doi-asserted-by":"crossref","unstructured":"Qiu X, Lu C, Sha H, Zhu Y, Kong W, Tong F, Wang Q, Meng F, Liu B, Du J. Efficacy and safety of second-line therapy by S-1 combined with sintilimab and anlotinib in pancreatic cancer patients with liver metastasis: a single-arm, phase II clinical trial. Front Immunol. 2024;15:1210859.","DOI":"10.3389\/fimmu.2024.1210859"},{"key":"1078_CR47","doi-asserted-by":"publisher","first-page":"785400","DOI":"10.3389\/fimmu.2021.785400","volume":"12","author":"Y Ye","year":"2021","unstructured":"Ye Y, Zheng S. Successful immunotherapy for pancreatic cancer in a patient with TSC2 and SMAD4 mutations: A Case Report. Frontiers in Immunology. 2021;12:785400.","journal-title":"Frontiers in Immunology"},{"key":"1078_CR48","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1038\/s41571-019-0281-6","volume":"17","author":"C Nevala-Plagemann","year":"2020","unstructured":"Nevala-Plagemann C, Hidalgo M, Garrido-Laguna I. From state-of-the-art treatments to novel therapies for advanced-stage pancreatic cancer. Nat Rev Clin Oncol. 2020;17:108\u201323.","journal-title":"Nat Rev Clin Oncol"},{"key":"1078_CR49","doi-asserted-by":"publisher","first-page":"2008","DOI":"10.1016\/S0140-6736(20)30974-0","volume":"395","author":"JD Mizrahi","year":"2020","unstructured":"Mizrahi JD, Surana R, Valle JW, et al. Pancreatic cancer. The Lancet. 2020;395:2008\u201320.","journal-title":"The Lancet"},{"key":"1078_CR50","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1126\/science.aan6733","volume":"357","author":"DT Le","year":"2017","unstructured":"Le DT, Durham JN, Smith KN, et al. Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. Science. 2017;357:409\u201313.","journal-title":"Science"},{"key":"1078_CR51","doi-asserted-by":"publisher","first-page":"2969","DOI":"10.12998\/wjcc.v9.i13.2969","volume":"9","author":"JH Yoon","year":"2021","unstructured":"Yoon JH, Jung Y-J, Moon S-H. Immunotherapy for pancreatic cancer. World journal of clinical cases. 2021;9:2969.","journal-title":"World journal of clinical cases"},{"key":"1078_CR52","doi-asserted-by":"publisher","first-page":"1642","DOI":"10.1053\/j.gastro.2005.03.039","volume":"128","author":"AC Lockhart","year":"2005","unstructured":"Lockhart AC, Rothenberg ML, Berlin JD. Treatment for pancreatic cancer: current therapy and continued progress. Gastroenterology. 2005;128:1642\u201354.","journal-title":"Gastroenterology"},{"key":"1078_CR53","first-page":"19","volume-title":"Seminars in oncology","author":"AG Raufi","year":"2019","unstructured":"Raufi AG, Manji GA, Chabot JA, et al. Neoadjuvant treatment for pancreatic cancer. In: Seminars in oncology. Elsevier; 2019. p. 19\u201327."},{"key":"1078_CR54","doi-asserted-by":"publisher","first-page":"5020","DOI":"10.1158\/1078-0432.CCR-21-0929","volume":"27","author":"B Bockorny","year":"2021","unstructured":"Bockorny B, Macarulla T, Semenisty V, et al. Motixafortide and pembrolizumab combined to nanoliposomal irinotecan, fluorouracil, and folinic acid in metastatic pancreatic cancer: the COMBAT\/KEYNOTE-202 Trial Motixafortide, Pembrolizumab, and Chemotherapy in PDAC. Clin Cancer Res. 2021;27:5020\u20137.","journal-title":"Clin Cancer Res"},{"key":"1078_CR55","doi-asserted-by":"publisher","first-page":"1670","DOI":"10.1158\/1078-0432.CCR-16-2319","volume":"23","author":"GA Manji","year":"2017","unstructured":"Manji GA, Olive KP, Saenger YM, et al. Current and emerging therapies in metastatic pancreatic cancer. Clin Cancer Res. 2017;23:1670\u20138.","journal-title":"Clin Cancer Res"},{"key":"1078_CR56","unstructured":"Bockorny M. pembrolizumab combined to nanoliposomal irinotecan, fluorouracil, and folinic acid in metastatic pancreatic cancer: the COMBAT\/KEYNOTE-202 Trial. Clin Cancer Res, clincanres CCR-21\u20130929-E 2021; 432\u20131078."},{"key":"1078_CR57","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13014-020-01569-5","volume":"15","author":"S Amin","year":"2020","unstructured":"Amin S, Baine M, Meza J, et al. The impact of immunotherapy on the survival of pancreatic adenocarcinoma patients who received definitive surgery of the pancreatic tumor: a retrospective analysis of the National Cancer Database. Radiat Oncol. 2020;15:1\u20139.","journal-title":"Radiat Oncol"},{"key":"1078_CR58","doi-asserted-by":"publisher","first-page":"2533","DOI":"10.3390\/jcm9082533","volume":"9","author":"A Mazloom","year":"2020","unstructured":"Mazloom A, Ghalehsari N, Gazivoda V, et al. Role of immune checkpoint inhibitors in gastrointestinal malignancies. J Clin Med. 2020;9:2533.","journal-title":"J Clin Med"},{"issue":"11","key":"1078_CR59","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1080\/1744666X.2022.2120471","volume":"18","author":"GC G\u00f6ssling","year":"2022","unstructured":"G\u00f6ssling GC, Zhen DB, Pillarisetty VG, Chiorean EG. Combination immunotherapy for pancreatic cancer: challenges and future considerations. Expert Rev Clin Immunol. 2022;18(11):1173\u201386.","journal-title":"Expert Rev Clin Immunol."},{"key":"1078_CR60","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13046-019-1153-8","volume":"38","author":"CK Looi","year":"2019","unstructured":"Looi CK, Chung FFL, Leong CO, et al. Therapeutic challenges and current immunomodulatory strategies in targeting the immunosuppressive pancreatic tumor microenvironment. J Exp Clin Cancer Res. 2019;38:1\u201323.","journal-title":"J Exp Clin Cancer Res"},{"key":"1078_CR61","doi-asserted-by":"publisher","DOI":"10.4161\/21624011.2014.962401","volume":"3","author":"ER Lutz","year":"2014","unstructured":"Lutz ER, Kinkead H, Jaffee EM, et al. Priming the pancreatic cancer tumor microenvironment for checkpoint-inhibitor immunotherapy. Oncoimmunology. 2014;3: e962401.","journal-title":"Oncoimmunology"},{"key":"1078_CR62","doi-asserted-by":"publisher","first-page":"3862","DOI":"10.3390\/cancers14163862","volume":"14","author":"T Brouwer","year":"2022","unstructured":"Brouwer T, Ijsselsteijn M, Oosting J, et al. A paradoxical role for regulatory t cells in the tumor microenvironment of pancreatic cancer. Cancers. 2022;14:3862.","journal-title":"Cancers"},{"key":"1078_CR63","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1038\/nri1936","volume":"6","author":"L Zitvogel","year":"2006","unstructured":"Zitvogel L, Tesniere A, Kroemer G. Cancer despite immunosurveillance: immunoselection and immunosubversion. Nat Rev Immunol. 2006;6:715\u201327.","journal-title":"Nat Rev Immunol"},{"key":"1078_CR64","first-page":"74","volume-title":"Seminars in cancer biology","author":"V Huber","year":"2017","unstructured":"Huber V, Camisaschi C, Berzi A, et al. Cancer acidity: an ultimate frontier of tumor immune escape and a novel target of immunomodulation. In: Seminars in cancer biology. Elsevier; 2017. p. 74\u201389."},{"key":"1078_CR65","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1038\/nrc3973","volume":"15","author":"I Melero","year":"2015","unstructured":"Melero I, Berman DM, Aznar MA, et al. Evolving synergistic combinations of targeted immunotherapies to combat cancer. Nat Rev Cancer. 2015;15:457\u201372.","journal-title":"Nat Rev Cancer"},{"key":"1078_CR66","doi-asserted-by":"publisher","first-page":"1010","DOI":"10.1016\/S0140-6736(20)32598-8","volume":"397","author":"F Meric-Bernstam","year":"2021","unstructured":"Meric-Bernstam F, Larkin J, Tabernero J, et al. Enhancing anti-tumour efficacy with immunotherapy combinations. The Lancet. 2021;397:1010\u201322.","journal-title":"The Lancet"},{"key":"1078_CR67","doi-asserted-by":"publisher","DOI":"10.1097\/SLA.0000000000003706","volume":"274","author":"BD Powers","year":"2021","unstructured":"Powers BD, Fulp W, Dhahri A, et al. The impact of socioeconomic deprivation on clinical outcomes for pancreatic adenocarcinoma at a high-volume cancer center: a retrospective cohort analysis. Ann Surg. 2021;274: e564.","journal-title":"Ann Surg"},{"key":"1078_CR68","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1089\/pancan.2020.0011","volume":"6","author":"MD Watson","year":"2020","unstructured":"Watson MD, Miller-Ocuin JL, Driedger MR, et al. Factors associated with treatment and survival of early stage pancreatic cancer in the era of modern chemotherapy: an analysis of the National Cancer Database. J Pancreatic Cancer. 2020;6:85\u201395.","journal-title":"J Pancreatic Cancer"},{"key":"1078_CR69","doi-asserted-by":"crossref","unstructured":"Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA: a cancer journal for clinicians 2018; 68: 7\u201330.","DOI":"10.3322\/caac.21442"},{"key":"1078_CR70","unstructured":"Amin MB. American Cancer Society. AJCC cancer staging manual Eight edition\/editor-in-chief, Mahul B Amin, MD, FCAP; 1024."},{"key":"1078_CR71","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1016\/j.canlet.2015.12.020","volume":"381","author":"K Foley","year":"2016","unstructured":"Foley K, Kim V, Jaffee E, et al. Current progress in immunotherapy for pancreatic cancer. Cancer Lett. 2016;381:244\u201351.","journal-title":"Cancer Lett"},{"issue":"9","key":"1078_CR72","doi-asserted-by":"publisher","first-page":"1584","DOI":"10.1038\/s41416-022-01876-6","volume":"127","author":"Z Dongye","year":"2022","unstructured":"Dongye Z, Li J, Wu Y. Toll-like receptor 9 agonists and combination therapies: strategies to modulate the tumour immune microenvironment for systemic anti-tumour immunity. Br J Cancer. 2022;127(9):1584\u201394.","journal-title":"Br J Cancer"},{"key":"1078_CR73","first-page":"1107","volume":"10","author":"T Zhang","year":"2022","unstructured":"Zhang T, Faber M, Pong E, et al. 1067 Synergistic combination of natural killer cell engagers (NKEs) with proinflammatory cytokines. Regular and Young Investigator Award. 2022;10:1107.","journal-title":"Regular and Young Investigator Award"},{"key":"1078_CR74","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1080\/17425255.2016.1196187","volume":"12","author":"NLX Syn","year":"2016","unstructured":"Syn NLX, Yong WP, Goh BC, et al. Evolving landscape of tumor molecular profiling for personalized cancer therapy: a comprehensive review. Expert Opin Drug Metab Toxicol. 2016;12:911\u201322.","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"1078_CR75","doi-asserted-by":"publisher","first-page":"3489","DOI":"10.18632\/oncotarget.27727","volume":"11","author":"ES Katayama","year":"2020","unstructured":"Katayama ES, Hue JJ, Bajor DL, et al. A comprehensive analysis of clinical trials in pancreatic cancer: what is coming down the pike? Oncotarget. 2020;11:3489.","journal-title":"Oncotarget"},{"key":"1078_CR76","doi-asserted-by":"publisher","first-page":"14764","DOI":"10.18632\/oncotarget.24483","volume":"9","author":"RA Wolff","year":"2018","unstructured":"Wolff RA, Wang-Gillam A, Alvarez H, et al. Dynamic changes during the treatment of pancreatic cancer. Oncotarget. 2018;9:14764.","journal-title":"Oncotarget"},{"key":"1078_CR77","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1016\/j.omto.2022.01.010","volume":"24","author":"D Yeo","year":"2022","unstructured":"Yeo D, Giardina C, Saxena P, et al. The next wave of cellular immunotherapies in pancreatic cancer. Mol Ther Oncolytics. 2022;24:561\u201376.","journal-title":"Mol Ther Oncolytics"}],"container-title":["Journal of Gastrointestinal Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12029-024-01078-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12029-024-01078-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12029-024-01078-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,27]],"date-time":"2024-08-27T03:34:12Z","timestamp":1724729652000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12029-024-01078-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,8]]},"references-count":77,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,9]]}},"alternative-id":["1078"],"URL":"https:\/\/doi.org\/10.1007\/s12029-024-01078-8","relation":{},"ISSN":["1941-6628","1941-6636"],"issn-type":[{"value":"1941-6628","type":"print"},{"value":"1941-6636","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,8]]},"assertion":[{"value":"9 June 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 July 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed Consent"}},{"value":"The authors declare no conflict of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}}]}}